Abstract
Background: Occult HBV infection (OBI) is defined by the persistence of HBV in the liver without serum HBsAg and HBVDNA. It represents a life-threatening event during immunosuppressive chemotherapies. An OBI occurs in approximately 18% of HBcAb + patients. International guidelines suggest surveillance for HBV markers in immunosuppressed patients. In Non-Hodgkin Lymphoma (NHL), the prevalence of OBI reactivation remains to be established.Methods: In order to determine the prevalence of occult HBV reactivation in a large cohort of patients during chemotherapy for NHL, we analysed 498 NHL patients in a centre of Southern Italy. We evaluated HBV markers, NHL type, treatment type and occurrence of HBV reactivation.Results: Forty % of patients were treated with monoclonal antibodies and 60.3% without. Ninety-six patients were HBcAb+, HBsAg-. HBV reactivation occurred in ten subjects of this subgroup. All of them were successfully treated with Lamivudine. None of the patients experienced liver-related death. The prevalence of OBI reactivation was of 10.42% in HBcAb + HBsAb- patients. This event occurred in 50% of patients treated with mild immunosuppressive therapies. Each reactivation was treated with Lamivudine.Discussion: This report suggests that a strict surveillance is important and cost-effective in HBcAb + HBsAg- NHL patients treated with mild immunosuppressive therapies, in order to detect an occult HBV reactivation.
| Original language | English |
|---|---|
| Article number | 31 |
| Journal | BMC Gastroenterology |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 17 2014 |
Fingerprint
Keywords
- HBV reactivation
- Immunosuppression
- Non Hodgkin Lymphoma
- Occult HBV infection
ASJC Scopus subject areas
- Gastroenterology
Cite this
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. / Masarone, Mario; De Renzo, Amalia; La Mura, Vincenzo; Sasso, Ferdinando C.; Romano, Marco; Signoriello, Giuseppe; Rosato, Valerio; Perna, Fabiana; Pane, Fabrizio; Persico, Marcello.
In: BMC Gastroenterology, Vol. 14, No. 1, 31, 17.02.2014.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma
AU - Masarone, Mario
AU - De Renzo, Amalia
AU - La Mura, Vincenzo
AU - Sasso, Ferdinando C.
AU - Romano, Marco
AU - Signoriello, Giuseppe
AU - Rosato, Valerio
AU - Perna, Fabiana
AU - Pane, Fabrizio
AU - Persico, Marcello
PY - 2014/2/17
Y1 - 2014/2/17
N2 - Background: Occult HBV infection (OBI) is defined by the persistence of HBV in the liver without serum HBsAg and HBVDNA. It represents a life-threatening event during immunosuppressive chemotherapies. An OBI occurs in approximately 18% of HBcAb + patients. International guidelines suggest surveillance for HBV markers in immunosuppressed patients. In Non-Hodgkin Lymphoma (NHL), the prevalence of OBI reactivation remains to be established.Methods: In order to determine the prevalence of occult HBV reactivation in a large cohort of patients during chemotherapy for NHL, we analysed 498 NHL patients in a centre of Southern Italy. We evaluated HBV markers, NHL type, treatment type and occurrence of HBV reactivation.Results: Forty % of patients were treated with monoclonal antibodies and 60.3% without. Ninety-six patients were HBcAb+, HBsAg-. HBV reactivation occurred in ten subjects of this subgroup. All of them were successfully treated with Lamivudine. None of the patients experienced liver-related death. The prevalence of OBI reactivation was of 10.42% in HBcAb + HBsAb- patients. This event occurred in 50% of patients treated with mild immunosuppressive therapies. Each reactivation was treated with Lamivudine.Discussion: This report suggests that a strict surveillance is important and cost-effective in HBcAb + HBsAg- NHL patients treated with mild immunosuppressive therapies, in order to detect an occult HBV reactivation.
AB - Background: Occult HBV infection (OBI) is defined by the persistence of HBV in the liver without serum HBsAg and HBVDNA. It represents a life-threatening event during immunosuppressive chemotherapies. An OBI occurs in approximately 18% of HBcAb + patients. International guidelines suggest surveillance for HBV markers in immunosuppressed patients. In Non-Hodgkin Lymphoma (NHL), the prevalence of OBI reactivation remains to be established.Methods: In order to determine the prevalence of occult HBV reactivation in a large cohort of patients during chemotherapy for NHL, we analysed 498 NHL patients in a centre of Southern Italy. We evaluated HBV markers, NHL type, treatment type and occurrence of HBV reactivation.Results: Forty % of patients were treated with monoclonal antibodies and 60.3% without. Ninety-six patients were HBcAb+, HBsAg-. HBV reactivation occurred in ten subjects of this subgroup. All of them were successfully treated with Lamivudine. None of the patients experienced liver-related death. The prevalence of OBI reactivation was of 10.42% in HBcAb + HBsAb- patients. This event occurred in 50% of patients treated with mild immunosuppressive therapies. Each reactivation was treated with Lamivudine.Discussion: This report suggests that a strict surveillance is important and cost-effective in HBcAb + HBsAg- NHL patients treated with mild immunosuppressive therapies, in order to detect an occult HBV reactivation.
KW - HBV reactivation
KW - Immunosuppression
KW - Non Hodgkin Lymphoma
KW - Occult HBV infection
UR - http://www.scopus.com/inward/record.url?scp=84896695494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896695494&partnerID=8YFLogxK
U2 - 10.1186/1471-230X-14-31
DO - 10.1186/1471-230X-14-31
M3 - Article
VL - 14
JO - BMC Gastroenterology
JF - BMC Gastroenterology
SN - 1471-230X
IS - 1
M1 - 31
ER -